



Your guide to help improve patient outcomes.

A 2023 Multi-Specialty Meta-Analysis of 84 studies shows that 3M™ Prevena™ Therapy has demonstrated significant improvement in key patient outcomes across multiple specialties.¹

46%

reduction
in surgical site complications¹
46 studies; p<0.001*

*Statistically significant

48%

reduction
in surgical site infections¹
65 studies; p<0.001*

36%

reduction
in reoperations¹
40 studies; p<0.001*

23%

reduction
in readmissions¹
24 studies; p<0.039*

Patient and procedure risk stratification backed by clinical evidence

While surgical patients may benefit from Prevena Therapy, patients at risk for complications such as surgical site infection may see added benefit. The following uses select study data²⁻¹⁷ to provide an illustrative guide to aid in risk stratification. This is not an all-inclusive list of risk factors. Clinicians are advised to use their clinical judgment to identify at-risk patients and procedures.

Start here

Patient Risk Stratification

► Does the patient have **at least one** of the following risk factors for developing surgical site complications?

- | | |
|--|---|
| <input type="checkbox"/> Obesity (e.g., BMI>30 kg/m ²) | <input type="checkbox"/> Non-aspirin anticoagulation |
| <input type="checkbox"/> Active tobacco use | <input type="checkbox"/> Staphylococcus aureus nasal colonization |
| <input type="checkbox"/> Diabetes mellitus | <input type="checkbox"/> Corticosteroid usage |
| <input type="checkbox"/> Advanced age | <input type="checkbox"/> Chronic obstructive pulmonary disease (COPD) |
| <input type="checkbox"/> Autoimmune disease | <input type="checkbox"/> Immunosuppression |
| <input type="checkbox"/> Chronic kidney disease | |

- | |
|--|
| <input type="checkbox"/> Preoperative steroid or immunosuppressant use |
| <input type="checkbox"/> Malignancy |
| <input type="checkbox"/> Diffuse atherosclerotic disease |
| <input type="checkbox"/> Pulmonary disease |
| <input type="checkbox"/> Chronic inflammatory disease |
| <input type="checkbox"/> Preoperative bile stent/drain |
| <input type="checkbox"/> Neoadjuvant chemotherapy |
| <input type="checkbox"/> Significant pannus |

- | |
|---|
| <input type="checkbox"/> Malnutrition |
| <input type="checkbox"/> Prosthetic vascular graft |
| <input type="checkbox"/> Elevated cardiac risk (hypertension, coronary heart disease, history of myocardial infarction) |
| <input type="checkbox"/> Dyslipidemia |
| <input type="checkbox"/> Hypercholesterolemia |
| <input type="checkbox"/> Hyperhomocysteinemia |

Yes

No

Procedure Risk Stratification

► Is the procedure **high risk**?

- | |
|--|
| <input type="checkbox"/> Emergency surgery |
| <input type="checkbox"/> Revision surgery |
| <input type="checkbox"/> Extended surgical time |
| <input type="checkbox"/> Traumatized soft tissue |
| <input type="checkbox"/> High-tension incision |

- | |
|--|
| <input type="checkbox"/> Multiple incisions |
| <input type="checkbox"/> Sternotomy |
| <input type="checkbox"/> Repeat incisions |
| <input type="checkbox"/> Extensive undermining |
| <input type="checkbox"/> Large soft tissue defects |
| <input type="checkbox"/> Breast reconstruction |

- | |
|--|
| <input type="checkbox"/> Post-bariatric abdominoplasty |
| <input type="checkbox"/> Soilage risk |
| <input type="checkbox"/> Above knee amputation |
| <input type="checkbox"/> Below knee amputation |
| <input type="checkbox"/> Synthetic graft implantations |

- | |
|---|
| <input type="checkbox"/> Pre- or post-operative stoma |
| <input type="checkbox"/> Contaminated or dirty wound |
| <input type="checkbox"/> Preexisting wound infection |
| <input type="checkbox"/> Previous radiation therapy |
| <input type="checkbox"/> Ascites |

Yes

No

Consider Prevena Therapy

For additional safety information and instructions for use, consult the 3M™ Prevena™ Incision Management System Clinician Guide or contact your local 3M representative.

Standard Dressing



Versatility that meets your patients' needs

3M offers an expansive portfolio of negative pressure therapy dressings for closed incisions in several configurations and sizes to meet the needs of the surgeon while providing coverage for various surgical procedures and anatomical locations.

Protect the incision

3M™ Prevena™ Therapy Dressings

Manage the environment of closed incision via continuous NPWT at -125mm/Hg



Manage the incision and surrounding soft tissue

3M™ Prevena Restor™ Dressings

Manage the incision and surrounding soft tissue via continuous NPWT at -125mm/Hg with expanded coverage for the incision and surrounding soft tissue



3M™ Prevena™ 125 Therapy Unit



7-day unit

3M™ Prevena™ Plus 125 Therapy Units

7-day unit

14-day unit*



*Dressing change required at 7 days.

References

1. Cooper HJ, Singh DP, Gabriel A, Mantyh C, Silverman R, Griffin L. Closed Incision Negative Pressure Therapy Versus Standard of Care Over Closed Surgical Incisions in the Reduction of Surgical Site Complications: A Systematic Review and Meta-Analysis of Comparative Studies. *Plastic and Reconstructive Surgery – Global Open*. 2023 Mar 16;11(3):e4722. 2. Willy C, Agarwal A, Andersen CA, De Santis G, Gabriel A, Grauhan O, Guerra OM, Lipsky BA, Malas MB, Mathiesen LL, Singh DP, Reddy VS. Closed incision negative pressure therapy: international multidisciplinary consensus recommendations. *Int Wound J*. 2017 Apr;14(2):385-398. **OPEN ACCESS** 3. Curran T, Alvarez D, Pastrana Del Valle J, Cataldo TE, Poylin V, Nagle D. Prophylactic closed incision negative pressure wound therapy is associated with decreased surgical site infection in high-risk colorectal surgery laparotomy wounds. *Colorectal Dis*. 2019 Jan. 21(1):110-118. **OPEN ACCESS** 4. Javed AA, Teinor J, Wright M, Ding D, Burkhart RA, Hundt J, Cameron JL, Makary MA, He J, Eckhauser FE, Wolfgang CL, Weiss MJ. Negative Pressure Wound Therapy for Surgical-site Infections: A Randomized Trial. *Annals of Surgery*. 2019 Jun;269(6):1034-1040. **PMID 31082899** 5. Zaidi A, El-Masry S. Closed incision negative pressure therapy in high-risk general surgery patients following laparotomy: a retrospective study. *Colorectal Disease*. 2017 Mar;19(3):283-287. **OPEN ACCESS** 6. Licari L, Campanella S, Carolla C, Viola S, Salamone G. Closed Incision Negative Pressure Therapy Achieves Better Outcome Than Standard Wound Care: Clinical Outcome and Cost-Effectiveness Analysis in Open Ventral Hernia Repair With Synthetic Mesh Positioning. *Cureus*. 2020;12(5):e8283. **OPEN ACCESS** 7. Ayuso SA, Elhage SA, Okorji LM, Kercher KW, Colavita PD, Heniford BT, Augenstein VA. Closed-Incision Negative Pressure Therapy Decreases Wound Morbidity in Open Abdominal Wall Reconstruction With Concomitant Panniculectomy. *Ann Plast Surg*. 2022 Apr 1;88(4):429-433. **PMID 34670966** 8. Cheong Chung JN, Ali O, Hawthornthwaite E, Watkinson T, Blyth U, McKigney N, Harji DP, Griffiths B. Closed incision negative pressure wound therapy is associated with reduced surgical site infection after emergency laparotomy: A propensity matched-cohort analysis. *Surgery*. 2021 May 26;S0039-6060(21)00334-2. **PMID 34052025** 9. Lakhani A, Jamel W, Riddiough GE, Cabalag CS, Stevens S, Liu DS. Prophylactic negative pressure wound dressings reduces wound complications following emergency laparotomies: A systematic review and meta-analysis. *Surgery*. 2022 Sep;172(3):949-954. **PMID 35779950** 10. Grauhan O, Navasardyan A, Hofmann M, Muller P, Stein J, Hetzer R. Prevention of poststernotomy wound infections in obese patients by negative pressure wound therapy. *Journal of Thoracic and Cardiovascular Surgery*. 2013 May;145(5):1387-92. **OPEN ACCESS** 11. Suelo-Calanca RL, Thomson R, Read M, Matheson E, Isaac E, Chaudhry M, Loubani M. The impact of closed incision negative pressure therapy on prevention of median sternotomy infection for high risk cases: a single centre retrospective study. *Journal of Cardiothoracic Surgery*. 2020 Aug 19;15(1):222. **OPEN ACCESS** 12. Higuera-Rueda CA, Emara AK, Nieves-Malloure Y, Klika AK, Cooper HJ, Cross MB, Guild GN, Nam D, Nett MP, Scuderi GR, Cushner FD, Piuze NS, Silverman RP. The Effectiveness of Closed-Incision Negative-Pressure Therapy Versus Silver-Impregnated Dressings in Mitigating Surgical Site Complications in High-Risk Patients After Revision Knee Arthroplasty: The PROMISES Randomized Controlled Trial. *J Arthroplasty*. 2021 Jul;36(7S):S295-S302.e14. **OPEN ACCESS** Note that the length of therapy may be outside the range recommended in the Instructions for Use. 13. Newman JM, Siqueira MBP, Klika AK, Molloy RM, Barsoum WK, Higuera CA. Use of Closed Incisional Negative Pressure Wound Therapy After Revision Total Hip and Knee Arthroplasty in Patients at High Risk for Infection: A Prospective, Randomized Clinical Trial. *Journal of Arthroplasty*. 2019 Mar;34(3):554-559. **OPEN ACCESS** Note that the length of therapy may be outside the range recommended in the Instructions for Use. 14. Gabriel A, Sigalove S, Sigalove N, Storm-Dickerson T, Rice J, Maxwell P, Griffin L. The impact of closed incision negative pressure therapy on postoperative breast reconstruction outcomes. *Plastic and Reconstructive Surgery Global Open*. 2018 Aug; 6(8):e1880. **OPEN ACCESS** 15. Kwon J, Staley C, McCullough M, Goss S, Arosemena M, Abai B, Salvatore D, Reiter D, DiMuzio P. A randomized clinical trial evaluating negative pressure therapy to decrease vascular groin incision complications. *J Vasc Surg*. 2018 Dec;68(6):1744-1752. **OPEN ACCESS** 16. Gombert A, Babilon M, Barbat ME, Keszei A, von Trotha KT, Jalaie H, Kalder J, Kotelis D, Greiner A, Langer S, Jacobs MJ, Grommes J. Closed Incision Negative Pressure Therapy Reduces Surgical Site Infections in Vascular Surgery: A Prospective Randomised Trial (AIMS Trial). *Eur J Vasc Endovasc Surg*. 2018 Sept; 56(3):442-448. **OPEN ACCESS** 17. Plegler SP, Nink N, Elzien M, Kunold A, Koshty A, Böning A. Reduction of groin wound complications in vascular surgery patients using closed incision negative pressure therapy (ciNPT): a prospective, randomised, single-institution study. *International Wound Journal*. 2018 Feb;15(1):75-83. **OPEN ACCESS**

Help advance the standard of care.



3M Company
2510 Conway Ave.
St. Paul, MN 55144 USA

Phone 1-800-275-4524
(NPWT products)
1-800-228-3957

Web 3m.com/medical

3M™ Prevena™ 125 Therapy Unit and 3M™ Prevena™ Plus 125 Therapy Unit manage the environment of closed surgical incisions and remove fluid away from the surgical incision via the application of -125mmHg continuous negative pressure. When used with legally marketed compatible dressings, Prevena 125 and Prevena Plus 125 Therapy Units are intended to aid in reducing the incidence of seroma; and, in patients at high risk for post-operative infections, aid in reducing the incidence of superficial surgical site infection in Class I and Class II wounds.

The effectiveness of Prevena Therapy in reducing the incidence of SSIs and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at hcbgregulatory.3m.com.

The 3M™ Prevena Restor™ Incision Management System is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy.



Contact your 3M Sales Representative to learn more or visit prevena.com

Prevena for patients:
prevena.com/patients

NOTE: Specific indications, limitations, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. Rx only.

© 2023 3M. All rights reserved. 3M and the other marks shown are marks and/or registered trademarks. Unauthorized use prohibited.

70-2013-1637-2